Vaccine maker Novavax announced on Monday (June 14) that its vaccine is more than 90% effective against other variants of COVID-19.
The announcement was based on late-stage data from a clinical trial conducted with almost 30,000 volunteers in the United States. According to the company, the vaccine is 93% effective against COVID-19 and its variants.
The clinical trial also showed that the Novavax vaccine is 91% effective among volunteers at high risk of severe infection, and is 100% effective against moderate and severe COVID-19 cases.
(PTV News)/NGS- jlo
